Answers are grounded in this paper and cite their sources.
Lu-PSMA radioligand therapy, with only minimal grade 3 and 4 toxicities reported so far, it has the potential to expand options for metastatic castration-resistant PC. This review is intended to provide a comprehensive overview of the current literature on low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on agents that have been clinically adopted.
No takes yet. Share an insight, caveat, or question.
Eiber et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: